Prevalence of work-related common psychiatric disorders in primary care: The French Héraclès study.

General practitioners (GP), on the frontline for individuals with mental health problems, often deal with work-related common psychiatric disorders. We aimed to determine the prevalence of work-related common psychiatric disorders in general practice and associated patients' and GPs' characteristics. HERACLES, a cross-sectional study among 2019 working patients of 121 GPs in the Nord - Pas-de-Calais region in France. Common psychiatric disorders were assessed using the MINI International Neuropsychiatric Interview, patient-perceived psychological distress and GP-diagnosed psychiatric disorders. The work-relatedness of common psychiatric disorders was ascertained by the GP and/or the patient. Prevalence rates adjusted on age were calculated by sex and associated characteristics were ascertained using multilevel Poisson regression models. The prevalence of work-related common psychiatric disorders ascertained using the MINI was estimated at 25.6% [23.7-27.5], 24.5% [22.6-26.4] for self-reported psychological distress and 25.8% [23.9-27.7] for GP-diagnosed psychiatric disorders. Age, history of psychiatric disorders, consultation for psychological purpose and GP's characteristics were associated with MINI-identified psychiatric disorders. The prevalence of work-related common psychiatric disorders among working adults seen in general practice is high but further studies are needed to support this results.

Tropisetron for treating established postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled study.

UNLABELLED: Tropisetron can prevent postoperative nausea and vomiting (PONV) at doses smaller than those used to control chemotherapy-induced nausea and vomiting. In this placebo-controlled study, the efficacy and tolerability of three different doses of tropisetron were compared for the treatment of established PONV after surgical procedures in general anesthesia. Of 1513 patients who satisfied inclusion criteria, 314 experiencing PONV during the first 2 h after recovery from anesthesia were treated with one of three different doses of tropisetron (0.5, 2, or 5 mg) or placebo, administered i.v. as a single dose. Patients were then observed during 24 h for efficacy and tolerability. All three doses of tropisetron were significantly better than placebo in controlling emetic episodes and in reducing the need for rescue treatment. There were no significant differences among the three doses. However, in the subgroup of patients who had previous PONV, and in those randomized for nausea alone, the 2-mg and 5-mg doses controlled emetic episodes better than the 0.5-mg dose. All studied doses of tropisetron were well tolerated and did not affect vital signs. We conclude that a single i.v. administration of tropiestron significantly reduces the recurrence of emetic episodes in patients with established PONV after elective surgery with general anesthesia. Its optimal dose seems to be 2 mg. IMPLICATIONS: Three hundred-fourteen patients suffering from postoperative nausea and vomiting received different i.v. doses of a new antiemetic drug, tropisetron, to determine the lowest effective dose. We found that a single i.v. administration of tropisetron significantly reduced postoperative nausea and vomiting after elective surgery with general anesthesia.

Single dose i.v. tropisetron in the prevention of postoperative nausea and vomiting after gynaecological surgery.

In a prospective, randomized, multicentre, double-blind, placebo-controlled study, we have compared the efficacy of a single i.v. dose of tropisetron 0.5 mg, 2 mg and 5 mg in the prevention of postoperative nausea and vomiting (PONV). We studied 385 ASA class I and II female patients undergoing abdominal or vaginal gynaecological surgery, including laparoscopy. Tropisetron or placebo were administered before a standardized general anaesthetic. The frequency of vomiting in the 24-h period after entry into the recovery room was reduced from 44% after placebo to 31%, 26% and 30% after tropisetron 0.5 mg, 2 mg and 5 mg, respectively (P = 0.06, P = 0.009 and P = 0.043; unadjusted). Compared with placebo, nausea was reduced from 55% to 46%, 34% and 46% (P = 0.25, P = 0.003, P = 0.22), and need for rescue treatment from 39% to 29%, 23% and 35% (P = 0.13, P = 0.017 and P = 0.59) for the same groups. Tropisetron 2 mg appeared to be the optimal dose for prophylaxis against PONV with a side-effect profile similar to that of placebo.

Clinical evaluation of pulse oximetry monitors on critically ill patients.

Four pulse oximeters and two pulse oximeter-capnographs were evaluated on accuracy of measuring oxygen saturation and heartrate for the former and oxygen saturation, heartrate, respiratory rate and capnography for the latter. In the first part of the study four pulse oximeters (Criticare Systems Model 501 +, Ohmeda Biox 3700 Pulse Oximeter, Nellcor Model N 100 and Datex Satlite) were simultaneously studied on 10 ventilated ICU patients. Fifty simultaneous measurements were done for heartrate and oxygen saturation and compared to arterial saturations and ECG heartrates. Mean differences from pulse oximeter values versus control arterial and ECG values were within two percent for the four instruments. In the second part two oxicaps (Ohmeda 4700 and Nellcor N 1000) were evaluated with the same control parameters. Thirty measurements on 3 patients were done. As in the first part of the study all results were accurate within two percent of control values. From those data we can conclude that all examined monitors were fairly accurate compared to simultaneous arterial blood gas analysis and ECG monitoring. The oxicap monitors have the advantage of giving continuous information on two very important parameters of patient monitoring: CO2 and saturation.

A framework for a limitation policy of the population exposure to natural radiation in Belgium.

The conclusions are put forward that are adopted by a discussion group preparing the framework for a limitation policy of the radon problem in Belgium. Existing and future situations are treated in a coherent policy that is adequate for practical implementation. An action level is defined, together with a hierachy of levels for new constructions. The decision logic for the acceptance of building materials is explained.

N-Deformyl Vincristine a Bisalkaloid from Catharanthus roseus.

A bisalkaloid from CATHARANTHUS ROSEUS is N-deformyl vincristine (NDF). Its structure was clarified by spectroscopic methods.